Výsledky vyhledávání - "Yoji, Morisaki"

Akademický článek

Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis

Autor: Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh

Publikováno v: Acta Dermato-Venereologica, Vol 104 (2024)

Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low- to mid-potency topi

Externí odkaz: https://doaj.org/article/d0701168569e406880f281dc5bf863a8

Zobrazit plný text záznamu

Akademický článek

Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Autor: Hideto Kameda, Kohei Hagimori, Yoji Morisaki, Thorsten Holzkämper, Ayako Konomi, Hiroaki Dobashi

Publikováno v: Rheumatology and Therapy, Vol 10, Iss 6, Pp 1683-1703 (2023)

Abstract Introduction The efficacy and safety of ixekizumab, an anti-interleukin-17A antibody, in patients with severe symptoms of psoriatic arthritis are largely unexplored. We report the efficacy and safety of ixekizumab in a post hoc analysis of t

Externí odkaz: https://doaj.org/article/7a836e55396f4d16b31cc275841b7d4d

Zobrazit plný text záznamu

Akademický článek

Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Autor: Hideto Kameda, Kohei Hagimori, Yoji Morisaki, Thorsten Holzkämper, Ayako Konomi, Hiroaki Dobashi

Publikováno v: Rheumatology and Therapy, Vol 11, Iss 4, Pp 1057-1057 (2024)

Externí odkaz: https://doaj.org/article/7c9a0f093c4e4139832b0dd9875a333f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Autor: Akimichi Morita, Yukari Okubo, Yoji Morisaki, Hitoe Torisu-Itakura, Yoshinori Umezawa

Publikováno v: Dermatology and Therapy

Introduction In 2018, ixekizumab (80 mg every 2 weeks [Q2W] beyond Week 12) received approval in Japan for patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). This open-label study evaluated the efficacy and safety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb8369c0e9007892ac9654587a6c8bd
https://pubmed.ncbi.nlm.nih.gov/34967916

Zobrazit plný text záznamu

Long‐term efficacy and safety results from an open‐label phase III study ( UNCOVER ‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Autor: Hidehisa Saeki, Yoshinori Umezawa, Hitoe Torisu-Itakura, H. Elmaraghy, Yoji Morisaki, Ko Nakajo, N Akashi

Publikováno v: Journal of the European Academy of Dermatology and Venereology

Background Long‐term management of moderate‐to‐severe psoriasis is usually discussed in terms of continuous administration; however, there are many situations in clinical practice where treatment may be withdrawn with subsequent retreatment. Ob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0342e40c6c62328920c40ae645e54398
https://doi.org/10.1111/jdv.15292

Zobrazit plný text záznamu

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)

Autor: Keiji Iwatsuki, H. Elmaraghy, Yoji Morisaki, Yukari Okubo, Ko Nakajo, Hitoe Torisu-Itakura, Tomotaka Mabuchi

Publikováno v: Journal of the European Academy of Dermatology and Venereology

Background Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previous reports, we documented 24‐ and 52‐week findings of an open‐label, phase 3 trial (UNCOVER‐J) of ixekizumab in Japanese pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce2a2d4496a5328b1d217251f85d5743
http://europepmc.org/articles/PMC6587497

Zobrazit plný text záznamu

Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: Analyses of data pooled from three randomized, double-blind, placebo-controlled studies

Autor: Lars Viktrup, Masahiro Murakami, Osamu Nishizawa, Osamu Yokoyama, Yoji Morisaki, Masayuki Takeda, Masaki Yoshida

Publikováno v: International Journal of Urology. 22:378-384

Objectives Assess the efficacy and safety of tadalafil 5 mg once-daily in Asian men with lower urinary tract symptoms by pooling data from three clinical studies. Methods Data on 1199 Japanese, Korean, and Taiwanese men given tadalafil 5 mg (n = 601)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::602cee15ac2d5616222bbf11d041560e
https://doi.org/10.1111/iju.12699

Zobrazit plný text záznamu

Plný text ve formátu HTML

Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia

Autor: Yoji Morisaki, Tamio Teramoto, Giacomo Ruotolo, Kathryn A. Krueger, Masakazu Takeuchi

Publikováno v: The American Journal of Cardiology. 113(12):2021-2029

The cholesteryl ester transfer protein (CETP) inhibitor evacetrapib has been previously shown to increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) levels, as monotherapy or in combination w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8447defacdc2f1a014dbffaf74009138

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání